Celldex Therapeutics (CLDX) Accumulated Expenses (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Accumulated Expenses of $38.4 million for Q1 2026, up 50.92% year-over-year from $25.5 million in Q1 2025, and down 18.31% quarter-over-quarter from $47.0 million in Q4 2025.
Celldex Therapeutics (CLDX) Accumulated Expenses (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $38.4 million for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 50.92% year-over-year to $38.4 million; the TTM figure through Mar 2026 stood at $38.4 million (up 50.92% YoY), while the FY2025 annual figure was $47.0 million, up 306.54% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $38.4 million, down from $47.0 million in the prior quarter.
- The five-year high for Accumulated Expenses was $47.0 million in Q4 2025, with the low at $7.5 million in Q4 2022.
- The 5-year median for Accumulated Expenses is $17.5 million (2024), against an average of $20.2 million.
- The sharpest annual moves came in 2022 and 2025: Accumulated Expenses tumbled 37.28% in 2022, then jumped 306.54% in 2025.
- Celldex Therapeutics' Accumulated Expenses stood at $7.5 million in 2022, then advanced by 24.21% to $9.3 million in 2023, then gained by 23.75% to $11.6 million in 2024, then jumped by 306.54% to $47.0 million in 2025, then fell by 18.31% to $38.4 million in 2026.
- Business Quant data shows CLDX's Accumulated Expenses at $38.4 million in Q1 2026, $47.0 million in Q4 2025, and $39.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.86 Mn |
| Mar 31, 2026 | 38.42 Mn |
| Dec 31, 2025 | 47.03 Mn |
| Sep 30, 2025 | 39.72 Mn |
| Jun 30, 2025 | 28.42 Mn |
| Mar 31, 2025 | 25.46 Mn |
| Dec 31, 2024 | 11.57 Mn |
| Sep 30, 2024 | 28.20 Mn |
| Jun 30, 2024 | 18.59 Mn |
| Mar 31, 2024 | 17.54 Mn |
| Dec 31, 2023 | 9.35 Mn |
| Sep 30, 2023 | 18.47 Mn |
| Jun 30, 2023 | 12.26 Mn |
| Mar 31, 2023 | 9.37 Mn |
| Dec 31, 2022 | 7.53 Mn |
| Sep 30, 2022 | 11.43 Mn |
| Jun 30, 2022 | 11.23 Mn |
| Mar 31, 2022 | 9.23 Mn |
| Dec 31, 2021 | 12.00 Mn |
| Sep 30, 2021 | 10.25 Mn |